ABPM Addiction Medicine common mistakes
ABPM Addiction Medicine · Understand the traps and how to avoid them.
Choosing an immediate detoxification or residential admission as the answer whenever a vignette shows heavy use, without first matching the patient to the least restrictive effective level of care.
Candidates equate severity of use with severity of setting and skip the ASAM criteria dimensions (withdrawal risk, biomedical, psychiatric, readiness, relapse potential, recovery environment).
What to do instead
For every treatment-setting item, explicitly score the six ASAM dimensions in the stem, then select the lowest level that safely manages the highest-risk dimension; reserve inpatient for clear withdrawal or biomedical danger.
Treating a positive urine drug screen as proof of new use in a patient on agonist therapy, rather than interpreting it against the prescribed medication and expected metabolites.
Candidates forget that buprenorphine, methadone, and their metabolites are expected findings and that assay cutoffs and cross-reactivity vary.
What to do instead
Before answering, list what the prescribed drug should produce on the panel; only call a result inconsistent use when the detected substance or metabolite cannot come from the prescribed regimen.
Failing to recognize and treat alcohol withdrawal as a medical emergency, or selecting a benzodiazepine-sparing regimen in a patient with a history of complicated withdrawal.
Candidates underweight autonomic signs and prior seizure or delirium history, and overgeneralize newer adjunct strategies.
What to do instead
Anchor on CIWA-type severity plus prior complicated withdrawal; choose symptom-triggered benzodiazepines with thiamine and glucose precautions, and avoid relying on adjuncts alone in high-risk patients.
Missing co-occurring psychiatric illness or attributing all symptoms to substance use, or the reverse, without applying a timeline to distinguish intoxication, withdrawal, and independent disorders.
Candidates accept the "substance-induced" label too quickly or dismiss it too quickly, without checking whether symptoms persist beyond an expected window of abstinence.
What to do instead
In each vignette, note time since last use and expected duration of intoxication/withdrawal; diagnose an independent disorder when symptoms persist or predate use, and plan integrated treatment rather than sequential referral.
Recommending abrupt discontinuation of long-term benzodiazepines, alcohol, or barbiturates without a taper, or tapering opioids in a way that risks destabilization.
Candidates apply general "stop the offending drug" logic without accounting for withdrawal danger and loss of tolerance.
What to do instead
Before recommending discontinuation, classify the drug's withdrawal risk; for GABAergic agents plan a gradual structured taper, and for opioids coordinate tapering with retention and overdose-prevention planning.
Overlooking prescription drug monitoring data and converging prescriptions when a patient presents with escalating opioid or stimulant requests.
Candidates focus on the stated complaint and do not routinely incorporate PDMP review, pill counts, or urine testing into the assessment.
What to do instead
Treat PDMP review and objective monitoring as standard elements of any controlled-substance encounter; when red flags appear, address them with a documented plan rather than immediate dismissal or unconditional continuation.
Failing to offer or discuss evidence-based pharmacotherapy for opioid use disorder, or requiring counseling or abstinence as a precondition for medication.
Candidates default to psychosocial-only treatment or impose barriers not supported by evidence, conflating agonist therapy with substituting one addiction for another.
What to do instead
Make buprenorphine or methadone the default offer for OUD with a clear rationale; state that counseling is additive, not prerequisite, and that medication reduces mortality.
Not providing or counseling on naloxone and overdose-prevention education to patients at risk or their household members.
Candidates treat overdose prevention as separate from the treatment plan and forget take-home naloxone as a routine discharge element.
What to do instead
For any patient with opioid use, prior overdose, or high-dose prescription opioids, include naloxone provision and bystander training in the plan and name it explicitly in the answer choice.
Using stigmatizing language or framing abstinence as the only valid outcome, and failing to incorporate harm reduction and recovery supports such as peer services and mutual-help groups.
Candidates equate successful treatment with complete abstinence and overlook patient-centered goals and recovery capital.
What to do instead
Select answers that use person-first language, meet patients at their stated goals, and combine medication, harm reduction, and recovery supports tailored to the patient's preferences.
Ignoring or mishandling the family in vignettes, either by excluding them or by breaching the patient's confidentiality, instead of assessing family impact and offering appropriate support and referral.
Candidates do not distinguish the family's own care needs from the patient's record, and miss codependency, safety, and child-welfare considerations.
What to do instead
Separately assess family members' health and functioning, offer family-focused and mutual-support resources, and share patient information only with consent or as legally required, documenting any safety-driven disclosure.